Your browser doesn't support javascript.
loading
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.
Del Re, Marzia; Bordi, Paola; Rofi, Eleonora; Restante, Giuliana; Valleggi, Simona; Minari, Roberta; Crucitta, Stefania; Arrigoni, Elena; Chella, Antonio; Morganti, Riccardo; Tiseo, Marcello; Petrini, Iacopo; Danesi, Romano.
Afiliação
  • Del Re M; Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Bordi P; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Rofi E; Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Restante G; Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Valleggi S; Pneumology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Minari R; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Crucitta S; Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Arrigoni E; Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Chella A; Pneumology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Morganti R; Section of Statistics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Petrini I; Pneumology Unit, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy. iacopo.petrini@unipi.it.
  • Danesi R; Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Br J Cancer ; 119(10): 1252-1258, 2018 11.
Article em En | MEDLINE | ID: mdl-30397287
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Ácidos Nucleicos Livres / Compostos de Anilina / Neoplasias Pulmonares / Mutação / Antineoplásicos Limite: Adult / Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acrilamidas / Carcinoma Pulmonar de Células não Pequenas / Ácidos Nucleicos Livres / Compostos de Anilina / Neoplasias Pulmonares / Mutação / Antineoplásicos Limite: Adult / Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália